<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99222">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01989858</url>
  </required_header>
  <id_info>
    <org_study_id>2010-021052-25</org_study_id>
    <nct_id>NCT01989858</nct_id>
  </id_info>
  <brief_title>ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)</brief_title>
  <acronym>ITACA-S2</acronym>
  <official_title>ITACA-S2(Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach:Comparison of the Efficacy of a Peri-operative Versus a Post-operative Chemotherapy Treatment in Patients With Operable Gastric Cancer and Assessment of the Benefit of a Post-operative Chemo-radiotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mario Negri Institute for Pharmacological Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mario Negri Institute for Pharmacological Research</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study addresses two primary questions, according to its factorial design:

        -  to compare the efficacy in terms of overall survival (OS) of a peri-operative vs. a
           post-operative chemotherapy (CHT) treatment, irrespectively of the presence of a
           post-surgical chemo-radiotherapy (CHT-RTX) (Timing Study);

        -  to compare the efficacy in terms of relapse free survival (l-RFS)  of a post-surgical
           CHT-RTX treatment vs. no other treatment, irrespectively of the timing of CHT (RTX
           Study).

      The study has a 2x2 factorial design, thus consisting of two independent, following specific
      eligibility criteria and with different randomization scheme studies, the Timing Study and
      the RTX Study.

      Both studies are Italian, multicentre, open-label, randomized, superiority, phase III trials
      conducted in patients with histologically confirmed, localized gastric adenocarcinoma, which
      is considered operable.

      In the Timing Study patients fulfilling the eligibility criteria will be randomized with a
      1:1 ratio to receive:

        -  peri-operative CHT (Arm A) or

        -  post-operative CHT (Arm B) Once randomized in the Timing Study, patients may also be
           randomized in the RTX

      Study to receive in addition to CHT a post-operative CHT-RTX treatment or no other
      treatment. This is possible since the randomization will be done in two steps: the first for
      the Timing Study for all the participating centres (peri-operative CHT vs. post-operative
      CHT) and the second one for the RTX Study, only for those centres with the radiotherapist
      willing and able to participate (post- surgical CHT-RTX vs. no other treatment). Thus the
      following four arms will be generated:

        -  peri-operative CHT (Arm A)

        -  post-operative CHT (Arm B)

        -  peri-operative CHT  + post-operative CHT-RTX (Arm C)

        -  post-operative CHT  + post-operative CHT-RTX (Arm D) The study will be conducted in
           more than one hundred experimental centres. Follow-up F(-up) procedures and timing of
           the visits will be consistent with current clinical practice.

      Based on case-mix of sample 1000-1180 patients are needed in the Timing study and 420-520 in
      the RTX study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival (OS)- Timing Study</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS, defined for each patient as the time from the date of randomization to the date of death from any cause. Patients not reported as having died at the end of the study will be censored at the date they were last known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-intensity</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dose-intensity, that is the dose of effective drug administrated per unit time (mg/m2/week or Gy/week)
Dose and/or time modifications
Premature withdrawals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum toxicity grade</measure>
    <time_frame>up to 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximum toxicity grade experienced by each patient for each toxicity
Patients experiencing grade 3-4 toxicity for each toxicity
Type,frequency and nature of serious adverse events (SAEs)
Patients with at least a SAE
Patients with at least a serious adverse drug reaction (SADR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS) - Timing Study</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DFS, defined for each patient as the time from the date of randomization to the date of local or regional relapse, distant metastasis, second primary malignancy or death from any cause, whichever comes first. Patients not recurred, progressed or died while on study or lost to f-up will be censored at their last disease assessment date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival (l-RFS)- RTX Study</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>1-RFS, defined for each patient as the time from the date of randomization to the date of first local recurrence or death from any cause, whichever comes first.
Description:   1-RFS, defined for each patient as the time from the date of randomization to the date of first local recurrence or death from any cause, whichever comes first. Patients not locally recurred or died while on study or lost to f-up will be censored at their last disease assessment date</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1180</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>peri-operative CHT (Arm A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>post-operative CHT (Arm B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peri-operative CHT  + post-operative CHT-RTX (Arm C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In peri-operative CHT arm, CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>post-operative CHT  + post-operative CHT-RTX (Arm D)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>peri-operative cht</intervention_name>
    <description>CHT treatment have to be chosen between the following associations:
Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day  1 per os (po) continuously
or
Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.</description>
    <arm_group_label>peri-operative CHT (Arm A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>post-operative CHT</intervention_name>
    <description>CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day  1 per os (po) continuously
or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line.</description>
    <arm_group_label>post-operative CHT (Arm B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>peri-operative cht + post-operative cht-rtx</intervention_name>
    <description>CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day  1 per os (po) continuously or
ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:
5FU 225 mg/m² given as a continuous iv infusion or
capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.</description>
    <arm_group_label>peri-operative CHT  + post-operative CHT-RTX (Arm C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>post-operative cht + post-operative cht-rtx</intervention_name>
    <description>CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day  1 per os (po) continuously or
ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:
5FU 225 mg/m² given as a continuous iv infusion or
capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX.</description>
    <arm_group_label>post-operative CHT  + post-operative CHT-RTX (Arm D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt;18 years

          -  Eastern Cooperative Oncology Group - Performance Status (ECOG-PS) 0-1

          -  T3 or T4 carcinoma without lymphnode involvement (N0) and any T-stage with (N+)
             lymphnode involvement

          -  no distant metastases (M0)

          -  fitness to receive CHT and CHT-RTX

          -  no peripheral neuropathy greater than grade 1

          -  absence of peritoneal carcinomatosis

          -  written  informed  consents (one for each  trial) given before the randomization,
             according to International Conference on Harmonisation/Good Clinical Practice
             (ICH/GCP)

        Exclusion Criteria:

          -  adenocarcinoma of the gastro-esophageal junction

          -  previous CHT or RTX

          -  abnormal haematological, hepatic or renal functions, assessed within 7   days prior
             to randomization

          -  lymphnode metastases (biopsy proof, if possible) outside the loco-regional field,
             such as supraclavicular, mediastinal or para-aortic nodes

          -  positive peritoneal cytology

          -  clinical significant (i.e. active) cardiovascular disease for example cerebrovascular
             accidents (≤ 6 months), myocardial infarction (≤ 6 months), instable angina, New York
             Heart Association grade II or greater congestive heart failure, serious cardiac
             arrhythmia requiring medication

          -  lack of physical integrity of the upper gastrointestinal tract, malabsorption
             syndrome, or inability to take oral medication

          -  history or presence of other disease, metabolic dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates the use of an investigational drug or patients at high
             risk from treatment complications

          -  pregnancy or breast feeding. Women of childbearing potential and their parents must
             be willing to practice acceptable methods of birth control to prevent pregnancy

          -  presence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and f-up schedule
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>IRENE FLORIANI, BIOL.SCI.D.,STAT.D.,PH.D.</last_name>
    <phone>+39-02 39014695</phone>
    <email>irene.floriani@marionegri.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ROBERTO LABIANCA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. Ospedale Treviglio-Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <state>BG</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ANDREA ANGELO MARTONI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>CN</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria &quot;Policlinico-Vittorio Emanuele&quot;</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Mater Domini</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PIEROSANDRO TAGLIAFERRI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero- Universitaria Careggi - Firenze</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FRANCESCO DI COSTANZO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>PAOLO BIDOLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Desio e Vimercate</name>
      <address>
        <city>Vimercate</city>
        <state>MB</state>
        <zip>20059</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DANIELE FAGNANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MAURIZIO TOMIROTTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;San Paolo&quot;</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DARIS FERRARI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per la Cura e lo Studio dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ROBERTO BUZZONI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Europeo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>NICOLA FAZIO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ARMANDO SANTORO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura MultiMedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>MI</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ORNELLA GOTTARDI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. &quot;Carlo Poma&quot;</name>
      <address>
        <city>Mantova</city>
        <state>MN</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ENRICO AITINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Ramazzini &quot; di Carpi</name>
      <address>
        <city>Carpi</city>
        <state>MO</state>
        <zip>41012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>FABRIZIO ARTIOLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Guglielmo da Saliceto&quot;</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>LUIGI CAVANNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>VITTORINA ZAGONEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia e Dolce - USL 4</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Croce Fano</name>
      <address>
        <city>Fano</city>
        <state>PU</state>
        <zip>61032</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>RODOLFO MATTIOLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera 'San Carlo'</name>
      <address>
        <city>Potenza</city>
        <state>PZ</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>DOMENICO BILANCIA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova Azienda Ospedaliera</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ERMANNO RONDINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università &quot;Campus Bio-Medico&quot;</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>GIUSEPPE TONINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>CARLO ANTONIO MARIO BARONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. della Valtellina e della Valchiavenna - &quot;Ospedale E. Morelli&quot;</name>
      <address>
        <city>Sondalo</city>
        <state>SO</state>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCC/FPO -Istituto per la Ricerca e la Cura del Cancro di Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MASSIMO AGLIETTA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A. O. &quot;Ospedale di Circolo di Busto Arsizio&quot; - Busto Arsizio (VA)</name>
      <address>
        <city>Busto Arsizio</city>
        <state>VA</state>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A. O. Busto Arsizio - P.O. Saronno</name>
      <address>
        <city>Saronno</city>
        <state>VA</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale di Circolo e Fondazione Macchi</name>
      <address>
        <city>Varese</city>
        <state>VA</state>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>GRAZIELLA PINOTTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione &quot;G. Pascale&quot; Istituto Tumori di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ROSSANA CASARETTI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>November 15, 2013</lastchanged_date>
  <firstreceived_date>June 16, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with histologically confirmed, localized gastric adenocarcinoma, that is considered operable. The bulk of disease must be localized in the stomach.</keyword>
  <keyword>Patients with adenocarcinoma of the gastro-esophageal junction are not eligible for study inclusion.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
